Skip to Content

Colesevelam Dosage

Applies to the following strength(s): 625 mg ; 3.75 g ; 1.875 g

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Diabetes Type 2

Oral Tablets:
-Once-daily dosing regimen: 3750 mg (6 tablets) orally once a day
-Twice-daily dosing regimen: 1875 mg (3 tablets) orally twice a day

Oral Suspension:
-Once-daily dosing regimen: One 3.75 g packet orally once a day
-Twice-daily dosing regimen: One 1.875 g packet orally twice a day

Comments:
-Doses provided are acceptable for use whether this drug is used as monotherapy or in combination with a statin.
-Due to tablet size, patients with difficulty swallowing should consider using the oral suspension.
-This drug can be taken at the same time as a statin or the 2 drugs may be dosed apart.

Uses: As an adjunct to diet and exercise to reduce elevated low density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with a HMG-CoA reductase inhibitor (statin); and as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus

Usual Adult Dose for Hyperlipoproteinemia Type IIa (Elevated LDL)

Oral Tablets:
-Once-daily dosing regimen: 3750 mg (6 tablets) orally once a day
-Twice-daily dosing regimen: 1875 mg (3 tablets) orally twice a day

Oral Suspension:
-Once-daily dosing regimen: One 3.75 g packet orally once a day
-Twice-daily dosing regimen: One 1.875 g packet orally twice a day

Comments:
-Doses provided are acceptable for use whether this drug is used as monotherapy or in combination with a statin.
-Due to tablet size, patients with difficulty swallowing should consider using the oral suspension.
-This drug can be taken at the same time as a statin or the 2 drugs may be dosed apart.

Uses: As an adjunct to diet and exercise to reduce elevated low density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with a HMG-CoA reductase inhibitor (statin); and as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus

Usual Pediatric Dose for Heterozygous Familial Hypercholesterolemia

Oral Suspension:
10 to 17 years:
-Once-daily dosing regimen: One 3.75 g packet orally once a day
-Twice-daily dosing regimen: One 1.875 g packet orally twice a day

Comments:
-Due to tablet size, the oral suspension is recommended in the pediatric population.

Use: For use as monotherapy or in combination with a statin to reduce LDL-C in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if, after an adequate trial of diet therapy, the following findings are present: LDL-C remains at 190 mg/dL or higher, or LDL-C remains at 160 mg/dL or higher and there is a positive family history of premature cardiovascular disease (CVD) or 2 or more other CVD risk factors are present

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

No adjustment recommended.

Precautions

Safety and efficacy have not been established in patients younger than 10 years nor in premenarchal girls.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Oral Suspension and Tablets: Take orally with meals and liquid
-Oral Suspension: For use in pediatric patients or in patients with difficulty swallowing tablets. To avoid esophageal distress, do not take dry powder.
-Administer concomitant medications at least 4 hours prior to taking this drug

Storage requirements:
-Oral Suspension and Tablets: Store at room temperature; protect from moisture.
-Tablets: Brief exposure to 40C (104F) does not adversely affect the product.

Reconstitution/preparation techniques:
-Oral Suspension: Empty entire contents of 1 packet into a glass with 1/2 to 1 cup (4 to 8 ounces) of water, fruit juice, or diet soft drinks; stir well and drink.

General:
-Drug therapy should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacologic interventions alone have proven inadequate.
-Maximum therapeutic response to the lipid-lowering effects were achieved within 2 weeks and maintained during long term therapy; therapeutic response in diabetes clinical studies as reflected by reduction in HbA1c at 4 to 6 weeks after initiating treatment and reached maximal or near-maximal effect after 12 to 18 weeks of treatment.
-This drug has not been studied in type 2 diabetes in combination with a dipeptidyl peptidase 4 inhibitor, in pediatric patients with type 2 diabetes, Fredrickson Types I, III, IV, and V dyslipidemias, nor for the treatment of type 1 diabetes or diabetic ketoacidosis.

Monitoring:
-Metabolic: Measure lipid levels 4 to 6 weeks after initiating therapy.

Patient advice:
-Discontinue therapy and seek medical attention if symptoms of acute pancreatitis occur (e.g., severe abdominal pain with or without nausea/vomiting).
-This drug may cause constipation; a diet that promotes bowel regularity is recommended.
-Seek medical advice immediately if severe abdominal pain or severe constipation occurs.

Hide